

For your patients who got a second chance in life

Choose only the Original

that will give you


The **ADVANTAGE** you need

The **ADVANTAGE** of

ADVAGRAF[®]
Tacrolimus prolonged release hard capsule

Available in 0.5mg, 1mg and 3mg

Indicated for prophylaxis of transplant rejection in adult kidney or liver allograft recipients²



Dear Dr. {{accFname}} {{accLname}},


• **ADVAGRAF is effective and well tolerated in long-term in denovo liver transplant patients¹** •

Retrospective analysis from the European Liver Transplant registry with 1002 patients on Advagraf and 2004 patients on BID Tacrolimus


[Click Here](#)

For more information on the method and population

Graft survival



Patient survival



Conclusion-

- 1) Improvements in graft and patient survival with Advagraf versus twice-daily tacrolimus were observed as early as 3 months after transplantation and continued over 4 years¹
- 2) Tacrolimus OD dosing resulted in a 6% improved graft survival compared with BID dosing.¹
- 3) Tacrolimus OD dosing resulted in a 5% improved patient survival compared with BID dosing.¹

Sincerely,

{{userName}}

{{User.Title}}

Tel: {{User.Phone}}

Email: {{User.Email}}



Report any adverse events to Astellas Pharma India Pvt. Ltd. at pv@in.astellas.com.
Astellas Pharma India Pvt. Ltd. 301, 3rd Floor, C 7 B Square, 126 Andheri Kurla Road, Chakala, Andheri East, Mumbai 400 069, India
To unsubscribe or manage your subscription preferences, please [click here](#).
For more information about your privacy rights and how we protect your personal information, please view our [privacy notice](#)

MAT-IN-ADV-2024-00026, valid upto May 2026